HTR2B
ENSG00000135914
Target class
GPCR
Chromosome
2
Approved drugs
7
Clinical candidates (approved and in development)
10
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- Yes
- Target name
- HTR2B
- Gene name
- 5-hydroxytryptamine receptor 2B
- Gene symbol
- HTR2B
- Protein name
- 5-hydroxytryptamine receptor 2B (5-HT-2B) (5-HT2B) (Serotonin receptor 2B)
- 5-HT(2B)
- 5-HT2B
- Gene biotype
- Protein coding
- Gene family
- 5-hydroxytryptamine receptors, G protein-coupled
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 19
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 14.9
- Tissue specificity (Gini)
- 0.717
- Tissue specificity (tau)
- 0.876
- KEGG gene identifiers
- hsa:3357
- Protein interaction confidence
- 0.858
- Protein interaction partners
- 19
- R-HSA-390666
- R-HSA-416476
- End position
- 231125080
- Start position
- 231108230
- Chromosome
- 2
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Synapse, synaptosome .
- Nucleoplasm
- PubMed 12970106
- PubMed 23519210
- PubMed 23519215
- PubMed 28129538
- PubMed 7926008
- PubMed 8078486
- PubMed 8143856
- PubMed 24357322
- Tissue specificity (tau)
- 0.875814
- Expression inequality (Gini)
- 0.71657
Expression in transcripts per million
- Adrenal Gland
- 14.9
- Uterus
- 14.58
- Cervix - Endocervix
- 13.83
- Colon - Sigmoid
- 9.33
- Esophagus - Muscularis
- 8.93
Expression in transcripts per million
- Adrenal Gland14.9
- Uterus14.58
- Cervix - Endocervix13.83
- Colon - Sigmoid9.33
- Esophagus - Muscularis8.93
- Cervix - Ectocervix6.26
- Esophagus - Gastroesophageal Junction5.1
- Thyroid4.63
- Fallopian Tube3.46
- Artery - Coronary3.24
- Artery - Aorta3.22
- Colon - Transverse2.78
- Heart - Atrial Appendage2.67
- Kidney - Medulla1.96
- Artery - Tibial1.58
- Kidney - Cortex1.44
- Bladder1.28
- Ovary1.12
- Vagina1.06
- Adipose - Subcutaneous0.97
- Cells - Cultured fibroblasts0.96
- Breast - Mammary Tissue0.94
- Adipose - Visceral (Omentum)0.91
- Lung0.66
- Small Intestine - Terminal Ileum0.59
And 29 more, listed on the interactive page.
- GO:0001819
- GO:0001938
- GO:0006874
- GO:0007186
- GO:0007208
- GO:0008284
- GO:0009410
- GO:0010513
- GO:0014827
- GO:0019722
- GO:0042310
- GO:0043123
- GO:0050795
- GO:0051209
- GO:0070371
- GO:0070374
- GO:0098664
- GO:0005654
- GO:0005737
- GO:0005886
- GO:0098666
- GO:0001587
- GO:0001965
- GO:0004993
- GO:0005515
- GO:0051378
increased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pain
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264cardiac development effect leading to cardiomyopathy (based on knockout mouse data)
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- clinical: cardiac development effect leading to cardiomyopathy (based on knockout mouse data)
Biological samples
- cardiovascular system
Evidence sourcehypertension
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: hypertension
Biological samples
- cardiovascular system
Evidence sourcedecreased anxiety
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased anxiety
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264pulmonary hypertension
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: pulmonary hypertension
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264cardiac valvulopathy
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: cardiac valvulopathy
Biological samples
- cardiovascular system
Evidence sourcecardiac valvulopathy
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cardiac valvulopathy
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastrointestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastrointestinal transit
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264cardiovascular malformations
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: cardiovascular malformations
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264
potential cardiac valvulopathy
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: potential cardiac valvulopathy
- cardiovascular system
- development
- pulmonary
PubMed 23197038possible cardiac effects, especially during embryonic development
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: possible cardiac effects, especially during embryonic development
- cardiovascular system
- development
- pulmonary
PubMed 23197038pulmonary hypertension
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: pulmonary hypertension
- cardiovascular system
- development
- pulmonary
PubMed 23197038
Related records
Trials (1,411)
- "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
- "Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"
- [11C]Yohimbine PET Study of alpha2-AR
- 12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
- 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
- 16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression
- 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
- 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
- A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
- A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
- A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
- A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
- a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial
- A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
- A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure
- A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease
- A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
- A Comparison Between Oral Melatonin With Nasal Sevoflurane Versus Oral Chloral Hydrate With Nasal Sevoflurane in Sedation of Children Undergoing Brain MRI
Drugs (61)
- Agomelatine
- Amisulpride Serotonin (5-HT) receptor antagonist
- Apomorphine
- Balovaptan
- Brexpiprazole
- Brolamfetamine
- Bromocriptine
- Cabergoline
- Capeserod
- Cariprazine
- Chlorophenylpiperazine
- Clothiapine Serotonin 2 (5-HT2) receptor antagonist
- Clozapine
- Dexfenfluramine Serotonin (5-HT) receptor agonist
- Dexfenfluramine hydrochloride Serotonin (5-HT) receptor agonist
- Ergotamine
- Flibanserin
- Fluoxetine
- Glemanserin
- Haloperidol